Our mission is to provide new therapies to patients with life limiting oncology and rare diseases that have few, if any, other treatment options.
Our goal is to build an international biopharmaceutical company developing and commercializing new therapies for oncology and rare diseases based on novel targets with strong scientific and biological rationale. We seek to commercialise some of our therapeutics in certain regions and indications and to partner where significantly more resources are needed to fully exploit the potential of the target.
Our clinical-stage, oncology and rare disease assets originated in pharmaceutical or biotechnology companies where for strategic reasons they were not being progressed. With the streamlined efficiency of a small company and with our internal expertise and external resources we are able to rapidly progress the products into late stage development and the planned subsequent commercialization or partnership.